Skip to main content

May 2015, Vol 8, No 3

Editorial
Did the “HEN” Lay a Rotten Egg?
David B. Nash, MD, MBA
Read More
Regulatory
Breaking the Bank: Three Financing Models for Addressing the Drug Innovation Cost Crisis
J.D. Kleinke, Nancy McGee, DrPH
Stakeholder Perspective
Financing Drug Innovation: Cost versus Cure
by Joseph R. Antos, PhD
Read More
Business
Demonstrating Value for Biosimilars: A Conceptual Framework
Sally Amanuel, MSc, MA, MBA, Paola Antonini, MD, PhD, Victoria Coutinho, MSc, PhD, Thomas Goss, PharmD, Zhihong Lai, PhD, Sotiris Rompas, Phd, Michael F. Murphy, MD, PhD
Stakeholder Perspective
Challenges Surrounding the New Biosimilars Landscape
by Michael Kleinrock
Read More
Business
Adherence to Insulin Pen Therapy Is Associated with Reduction in Healthcare Costs Among Patients with Type 2 Diabetes Mellitus
Machaon M. K. Bonafede, PhD, MPH, Arthi Chandran, MS, MPH, Laurence J Hirsch, MD, Betsy J Lahue, MPH, Sonali Nigam, MPH, Rita Saltiel-Berzin, RN, MPH, CDE, CHES
Stakeholder Perspective
Adherence to Antihyperglycemic Treatment Regimen Also Reduces Overall Costs
by Quang T. Nguyen, DO, FACE, FTOS
Read More
Conference Highlights AMCP
Payers’ Perspectives: Health Economics Outcomes in Managed Care
Charles Bankhead, Medical Writer
Read More

Results 1 - 5 of 5